8 Million
Women will be lost to ovarian cancer by 2050 if we do nothing. (World Ovarian Cancer Coalition 2024)
Join ProSeek Bio to change the status quo
Our Solution
To facilitate ovarian cancer (OC) detection through high accuracy pathology-grade blood tests that incorporate multiple glycoform biomarkers.
Target
99% sensitivity
95% specificity
We need your help to create better health outcomes for women
Clinicians involved in ovarian cancer diagnosis
-
Clinical input
-
Clinical study collaboration
​
Pathology laboratories with mass spectrometry
-
Scientific & regulatory input
-
Partnering for clinical implementation
Women’s health advocates
Input, education & outreach
Our founder designed the innovative LeMBA-MS glycoform biomarker platform technology, previously proven through licensing of esophageal cancer glycoform biomarkers.
A grant from the Ovarian Cancer Research Foundation enabled the discovery and initial validation of new early detection ovarian cancer biomarkers, with commercialization rights assigned to ProSeek Bio.
ProSeek Bio is developing multibiomarker in vitro diagnostic (IVD) kits for use on pathology labs’ clinical mass spectrometers:
OC-Triage Test
Blood to help doctors determine the requirement for surgery in women presenting with symptoms consistent with ovarian cancer
OC-Screen Test
Blood test for early detection in women at high risk of ovarian cancer, prior to symptoms.
